Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenic Priming With PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination With Pembrolizumab

NCT03805594 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT03805594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03805594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenic Priming With PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination With Pembrolizumab
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Completed
Start date
May 10, 2019
Completion date
January 10, 2024
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration levels of testosterone, castration-resistant prostate carcinoma, metastatic prostate carcinoma, prostate adenocarcinoma, stage iv prostate cancer, stage iva prostate cancer, stage ivb prostate cancer